Severe events are rare, and treatment discontinuation due to side effects is uncommon
Viking Therapeutics Sector: Dual and triple agonists for obesity, metabolic, and liver disease HQ: San Diego, CA Year Founded: 2012 Origin Story: The company built its pipeline around small molecule and peptide candidates licensed from academic and pharma sources, eventually advancing VK2735, a dual GLP-1/GIP receptor agonist designed to be the first such therapy available in both oral and injectable formulations
And when there are symptomsthings like fatigue, tingling hands, and feet, dizziness, and memory losstheyre often so non-specific that doctors wont always flag B12 deficiency as an obvious cause
Medically Supervised Every treatment is backed by board-certified surgeons with years of experience in internal health and aesthetic wellness
Each is backed by years of clinical evidence, geared for chronic weight management, and available through Klinic
Symptoms associated with NAION may include: Federal GLP-1 litigation is currently divided into two separate multidistrict litigations (MDLs) in the Eastern District of Pennsylvania, where lawsuits involving similar allegations and scientific evidence are being coordinated before a single federal judge
